Shares in Spanish pharmaceutical giant Grifols rocket after Alzheimer treatment revelation
Wednesday, October 31, 2018 @ 7:49 PM
Shares in pharmaceutical multinational Grifols skyrocketed on the Spanish stock exchange on Monday after the company announced the results of a clinical trial of a plasma replacement product that had succeeded in slowing the progress of cognitive decline in people with Alzheimer's.
Presenting the results at a conference in Barcelona, the company, a global producer of blood plasma derivatives, said trials of the product had shown a 61% deceleration in the progress of Alzheimer's in patients with moderate symptoms, offering the possibility of a new treatment channel for the neurodegenerative disease.
Ambar (Alzheimer Management By Albumin Replacement) was tested on 496 patients and combines the periodic extraction of plasma and its replacement with an albumen solution, a plasma protein.
The treatment is founded on the hypothesis that most amyloid beta, the main component of the amyloid plaques found in the brains of Alzheimer patients, circulates in plasma attached to the albumen. The extraction of this plasma could displace the amyloid beta from the brain to the plasma, limiting the impact of the illness on the cognitive function of the patient.
Read more at thinkSPAIN.com